BR9912296A - Co-adminiostração de inibidores acat e mmp para o tratamento de lesões ateroscleróticas - Google Patents

Co-adminiostração de inibidores acat e mmp para o tratamento de lesões ateroscleróticas

Info

Publication number
BR9912296A
BR9912296A BR9912296-0A BR9912296A BR9912296A BR 9912296 A BR9912296 A BR 9912296A BR 9912296 A BR9912296 A BR 9912296A BR 9912296 A BR9912296 A BR 9912296A
Authority
BR
Brazil
Prior art keywords
acat
administration
mmp inhibitors
treatment
atherosclerotic lesions
Prior art date
Application number
BR9912296-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Tromas Michael Andrew Bocan
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of BR9912296A publication Critical patent/BR9912296A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Pyridine Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Furan Compounds (AREA)
BR9912296-0A 1998-07-21 1999-06-18 Co-adminiostração de inibidores acat e mmp para o tratamento de lesões ateroscleróticas BR9912296A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9363998P 1998-07-21 1998-07-21
PCT/US1999/013948 WO2000004892A2 (en) 1998-07-21 1999-06-18 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions

Publications (1)

Publication Number Publication Date
BR9912296A true BR9912296A (pt) 2001-04-17

Family

ID=22239992

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9912296-0A BR9912296A (pt) 1998-07-21 1999-06-18 Co-adminiostração de inibidores acat e mmp para o tratamento de lesões ateroscleróticas

Country Status (25)

Country Link
EP (1) EP1098662A2 (cs)
JP (1) JP2002521328A (cs)
KR (1) KR20010083134A (cs)
CN (1) CN1310629A (cs)
AP (1) AP2001002035A0 (cs)
AU (1) AU4701799A (cs)
BG (1) BG105162A (cs)
BR (1) BR9912296A (cs)
CA (1) CA2335062A1 (cs)
CZ (1) CZ2001126A3 (cs)
EA (1) EA200100153A1 (cs)
EE (1) EE200100046A (cs)
HR (1) HRP20010055A2 (cs)
HU (1) HUP0102880A3 (cs)
ID (1) ID30030A (cs)
IL (1) IL140982A0 (cs)
IS (1) IS5809A (cs)
NO (1) NO20010291L (cs)
OA (1) OA11584A (cs)
PL (1) PL346011A1 (cs)
SK (1) SK502001A3 (cs)
TR (1) TR200100205T2 (cs)
WO (1) WO2000004892A2 (cs)
YU (1) YU3501A (cs)
ZA (1) ZA200100294B (cs)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1210401A (en) * 1999-11-05 2001-06-06 Warner-Lambert Company Prevention of plaque rupture by acat inhibitors
GT200000203A (es) 1999-12-01 2002-05-24 Compuestos, composiciones y metodos para estimular el crecimiento y elongacion de neuronas.
JP2003534239A (ja) * 1999-12-17 2003-11-18 ヴァージコア・インコーポレーテッド 新規なスクシナート化合物、組成物、並びに使用及び調製方法
WO2002020009A1 (fr) * 2000-09-01 2002-03-14 Sankyo Company, Limited Compositions medicales
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
WO2003082288A1 (en) * 2002-04-03 2003-10-09 Topotarget Uk Limited Carbamic acid compounds comprising a piperazine linkage as hdac inhibitors
JP4617449B2 (ja) * 2002-07-11 2011-01-26 ヴィキュロン ファーマシューティカルズ インコーポレイテッド 抗菌活性を有するn−ヒドロキシアミド誘導体
WO2011092284A1 (en) * 2010-01-29 2011-08-04 Euroscreen S.A. Novel amino acid derivatives and their use as gpr43 receptor modulators
CN104211695B (zh) * 2013-06-04 2017-04-12 中国医学科学院医药生物技术研究所 一组胺甲酰基苯磺酰类化合物的用途
US20180000817A1 (en) * 2015-01-15 2018-01-04 Biocant - Associação De Transferência De Tecnologia Treatment of hutchinson-gilford progeria syndrome and diseases related to vascular ageing
CN106831697B (zh) * 2017-03-15 2019-11-05 深圳市康道生物有限公司 川榛有效提取成分及其在防治动脉粥样硬化中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5366987A (en) * 1991-08-22 1994-11-22 Warner-Lambert Company Isoxazolyl-substituted alkyl amide ACAT inhibitors
US5491172A (en) * 1993-05-14 1996-02-13 Warner-Lambert Company N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
GEP20012511B (en) * 1995-08-04 2001-08-27 Warner Lambert Co Method for Lowering Level of Lipoproteins (a) in Serum or Plasma of Mammals, Method for Treatment of Peripheral Vascular Diseases or Restenosis
EA001561B1 (ru) * 1996-05-17 2001-04-23 Варнер-Ламберт Компани Бифенилсульфонамидные ингибиторы матричных металлопротеиназ
NZ333063A (en) * 1996-09-04 2000-12-22 Warner Lambert Co Dibenzofuran sulfonamide derivatives as matrix metalloproteinase inhibitors

Also Published As

Publication number Publication date
ID30030A (id) 2001-11-01
AU4701799A (en) 2000-02-14
IS5809A (is) 2001-01-12
HUP0102880A3 (en) 2002-11-28
CZ2001126A3 (cs) 2002-01-16
TR200100205T2 (tr) 2001-05-21
NO20010291D0 (no) 2001-01-18
HRP20010055A2 (en) 2002-04-30
WO2000004892A2 (en) 2000-02-03
CN1310629A (zh) 2001-08-29
YU3501A (sh) 2005-06-10
PL346011A1 (en) 2002-01-14
ZA200100294B (en) 2002-01-10
AP2001002035A0 (en) 2001-03-31
NO20010291L (no) 2001-01-18
KR20010083134A (ko) 2001-08-31
CA2335062A1 (en) 2000-02-03
OA11584A (en) 2004-07-20
EP1098662A2 (en) 2001-05-16
EA200100153A1 (ru) 2001-08-27
BG105162A (en) 2001-12-29
HUP0102880A2 (en) 2002-06-29
EE200100046A (et) 2002-06-17
SK502001A3 (en) 2002-06-04
IL140982A0 (en) 2002-02-10
JP2002521328A (ja) 2002-07-16
WO2000004892A3 (en) 2000-05-18

Similar Documents

Publication Publication Date Title
BR9912296A (pt) Co-adminiostração de inibidores acat e mmp para o tratamento de lesões ateroscleróticas
DE59909400D1 (de) Bipolares koagulations- und schneidgerät für die endoskopische chirurgie
BR0208578A (pt) Produtos e métodos para melhorar a higiene dental do animal
FR2827500B1 (fr) Plaque d'osteosynthese de l'extremite superieure de l'humerus
CY2014005I1 (el) Τοπικα συστηματα παροχης γελης για την θεραπευτικη αντιμετωπιση των διαταραχων δερματος
BR9914891A (pt) Processos para aperfeiçoamento de cura de ferimento
BR0014996A (pt) Método para prevenir ou melhorar a dor de um ferimento fechado cirurgicamente em um indivìduo, e, emplastro
BR9707325A (pt) Processo para o tratamento de um paciente afetado com uma doença mediada por il-1, composição farmacéutica e uso da mesma
BRPI0410503B8 (pt) composição tópica e uso da composição
FR2715309B1 (fr) Composition adhésive, à usage chirurgical, à base de collagène modifié par coupure oxydative et non réticulé.
BR0103256A (pt) Utilização de substâncias bioquìmicas para uma composição para a prevenção e tratamento de condições de saúde causadas por constrição de células de músculo liso em órgãos do corpo humano
CY1119190T1 (el) Χρηση αναστολεων της il-18 για αγωγη ή προληψη βλαβων του κνς
BR0010669A (pt) Método para o tratamento de fibrose usando um antagonista da subunidade alfa-4 da integrina
PT969845E (pt) Novas combinacoes terapeuticas de mirtazapina e agentes antipsicoticos, para tratamento ou profilaxia de desordens psicoticas
BRPI0408491A (pt) tratamento da doença de alzheimer
BR0317461A (pt) Composições tópicas absorventes de óleo e método para o uso das mesmas
EE200100553A (et) Saredutandi ja selle farmatseutiliselt vastuvõetavate soolade kasutamine meeleoluhäirete, kohanemishäirete või segatüüpi ärev-depressiivsete häirete raviks või vältimiseks kasulike ravimite valmistamiseks
BR0107960A (pt) Tratamento de condições alérgicas e inflamatórias
BR9814867A (pt) Método para tratar discinesias relacionadas a doenças ou induzidas por drogas
DE60021350D1 (de) Mmp-hemmer bei bindegewebserweichung
BR9811559A (pt) Agonistas tricìclicos de vasopressina
BR0309515A (pt) Curativos de ferimento condutivos e métodos de uso
BR0316451A (pt) Combinação sinergìstica compreendendo roflumilast e formoterol
BR0113646A (pt) Tratamento de distúrbios inflamatórios
BR9909476A (pt) Novos tratamentos para distúrbios nervosos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6O, 7O E 8O ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1913 DE 04/09/2007.